Cancer Focus Target primarily metastatic breast cancer and triple negative breast cancer with AX09, presenting a lead opportunity for collaborations with oncology departments, research institutions, and biotech distributors seeking novel antibody-based therapeutics.

Clinical Partnerships Historical engagement with notable organizations (Leidos) and leadership hires indicate a readiness for strategic partnerships and joint development ventures; approach as a potential collaborator for malaria vaccines or cancer therapeutics programs.

Early Stage Financials With modest revenue and a relatively small team, AgilVax may be open to co-development funding, milestone-based deals, and strategic alliances to scale from preclinical to clinical stages.

Leadership Network Experience on the board from industry veterans suggests leverageable introductions and advisory-based sales angles; identify board-aligned opportunities in oncology and infectious disease verticals for joint ventures.

Global Collaboration Past international-style partnerships (Malaria vaccine work) imply openness to global research collaborations; position as a gateway for multinational pharma and contract research organizations seeking cost-effective development programs.